ArticleJournal of cellular and molecular medicine2026
Specific Lipid Peroxidation Products in Erythrocytes and Their Relationship to the Pathogenesis of Alzheimer's Disease.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Alzheimer's disease (AD) is a highly complex and multifactorial disorder in which oxidative stress acts as a key amplifying mechanism in the disease progression. Lipofuscin-like pigments (LFP), end products of lipid peroxidation, reflect oxidative damage and are capable of crossing the blood-brain barrier into the circulation. Thus, erythrocyte-derived LFP may serve as peripheral indicators of brain-specific processes. In this study, we aimed to assess the specificity of previously identified LFP for AD pathology. We analysed erythrocyte-derived LFP in individuals with biomarker-verified AD pathology (n = 40) and non-AD cognitive disorders (n = 21) across the prodromal and dementia stages, and in cognitively unimpaired individuals (n = 19). AD individuals showed significantly higher LFP levels compared with both healthy controls (p < 0.003) and the non-AD group (p ≤ 0.001). Furthermore, LFP levels correlated with established AD biomarkers in CSF, including amyloid-beta (r > -0.566) and phosphorylated tau 181 (r < 0.477). Our findings suggest that LFP may serve as potential blood-based biochemical markers reflecting oxidative stress-related processes associated with AD pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.